MINERALYS THERAPEUTICS, INC. (MLYS) Current Ratio
- Current ratio · latest quarter: Value 34.46×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 34.46× | Current assets / current liabilities. $665.80M ÷ $19.32M ≈ 34.46× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 665.80M USD | Assets, Current |
| Current obligations | 19.32M USD | Liabilities, Current |
| Cash and equivalents | 138.27M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.07M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $665.80M | $19.32M | $138.27M | (m) | (m) | (m) | $1.07M | (m) | 34.46× |
| 2026-03-31 | $652.47M | $14.72M | $112.78M | (m) | (m) | (m) | $1.12M | (m) | 44.33× |
| 2025-12-31 | $661.39M | $15.11M | $172.92M | (m) | (m) | (m) | $2.02M | (m) | 43.76× |
| 2025-09-30 | $599.80M | $23.52M | $217.60M | (m) | (m) | (m) | $1.12M | (m) | 25.50× |
| 2025-06-30 | $335.27M | $22.17M | $101.79M | (m) | (m) | (m) | $3.16M | (m) | 15.12× |
| 2025-03-31 | $354.51M | $13.39M | $165.01M | (m) | (m) | (m) | $373.00K | (m) | 26.48× |
| 2024-12-31 | $205.35M | $14.65M | $114.09M | (m) | (m) | (m) | $479.00K | (m) | 14.02× |
| 2024-09-30 | $267.73M | $31.32M | $97.27M | (m) | (m) | (m) | $3.11M | (m) | 8.55× |
| 2024-06-30 | $318.00M | $28.40M | $67.86M | (m) | (m) | (m) | $1.71M | (m) | 11.20× |
| 2024-03-31 | $346.82M | $19.20M | $90.42M | (m) | (m) | (m) | $4.26M | (m) | 18.06× |
| 2023-12-31 | $249.10M | $10.48M | $49.30M | (m) | (m) | (m) | $601.00K | (m) | 23.76× |
| 2023-09-30 | $265.38M | $13.54M | $86.30M | (m) | (m) | (m) | $5.57M | (m) | 19.59× |
| 2023-06-30 | $269.49M | $6.21M | $101.14M | (m) | (m) | (m) | $2.20M | (m) | 43.42× |
| 2023-03-31 | $275.27M | $10.56M | $138.25M | (m) | (m) | (m) | $2.39M | (m) | 26.07× |
| 2022-12-31 | $112.81M | $8.07M | $87.70M | (m) | (m) | (m) | $1.91M | (m) | 13.98× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |